Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessMarkets

Small & Mid-caps shine! Over 50 stocks in BSE 500 rose 10-30% in a week

As many as 55 stocks in the S&P BSE 500 index rallied 10-30 percent in a week that includes names like Union Bank of India, SPARC, Hindustan Zinc, ABB India, Glenmark Pharma, etc. among others.

June 28, 2020 / 07:24 AM IST

Indian markets which started off on a strong note witnessed some profit-taking towards the close of the week but still benchmark indices managed to close with gains of over 1 percent for the week ended June 26.

The S&P BSE Sensex rose 1.2 percent while the Nifty50 gained 1.3 percent for the week ended June 26 compared with 3.5 percent rally seen in the S&P BSE Mid-cap index, and the S&P BSE Small-cap index closed with gains of 2.8 percent in the same period.

As many as 55 stocks in the S&P BSE 500 index rallied 10-30 percent in a week that includes names like Union Bank of India, SPARC, Hindustan Zinc, ABB India, Glenmark Pharma, BHEL, Bandhan Bank, Adani Gas, Indian Bank, IDBI Bank, Future Consumer, and Indian Overseas Bank, etc. among others.

Experts are of the view that small and mid-caps are playing catch-up, but investors should ignore the noise, and stay with quality. Despite the fact that buying is seen in many small and mid-caps, investors should not allocate more than 20 percent of their portfolio.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"Sheer underperformance and the oversold state of small and mid-cap stocks have resulted in outperformance when the market, in general, bounced back from lower levels. Cash market stocks in mid and small-cap space have always outperformed the indices after a major correction in their prices. So this time is no different," Umesh Mehta, Head of Research, Samco Securities told Moneycontrol.

"The small and mid-caps that made a top in 2018 followed by two to three years of major price cuts are now experiencing outperformance. However, long term investors should not get carried away by such outperformance and can have exposure to the extent of 20 percent in such small and mid-cap stocks with balance 80 percent in frontline large caps," he said.



BSE 500 26 June 1


BSE 500 26 June 2

Where are markets headed?

It was a roller coaster ride for investors in the week gone by, but the good part is that the S&P BSE Sensex closed above 35,000 while the Nfity50 reclaimed 10,300 levels.

Tracking positive global cues, rise in COVID-19 related cases, and geopolitical tension between India-China, the market climbed all wall of worries in the week gone by.

Investors should brace for more volatility as markets head into the July series. The rollover data suggests that long positions got rolled over that would keep the markets afloat, but a break above 10,553 (high of June 24) for the index to head towards 10,600-10,900 levels.

The Nifty formed a Doji kind of candle on Friday (June 26) and an indecisive formation on the weekly charts as well which suggests consolidation in the coming week.

“The Nifty on the weekly chart formed a high wave-type candle formation near the key upside resistance of 10,550-10,600 levels. Positive chart patterns like higher highs and higher lows continued as per weekly chart and Nifty is placed to form a new higher high of the sequence. But, still, there is no confirmation of any higher top reversal,” Nagaraj Shetti, Technical Research Analyst, HDFC Securities told Moneycontrol.

“The short term trend of Nifty has turned into positive, after the minor weakness from the highs. There is a possibility of further upside in the early next week and one may expect Nifty to retest the overhead resistance of 10,550-10,600 levels in the mid to later part of the coming week. Immediate support is placed at 10,280,” he said.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Kshitij Anand
Kshitij Anand is the Editor Markets at Moneycontrol.
first published: Jun 27, 2020 09:03 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347